Elligo Health Research improves clinical trial access by engaging the 97% of physicians currently not offering clinical research to their patients.
The Gastroenterology Group will now offer clinical trials, allowing it to introduce the latest advances in research to its patients.
As a result, the clinic’s patients have access — in the convenience of the clinic’s office — to treatments they might not otherwise have. The Gastroenterology Group recognises the importance of conducting clinical research for its patients and community and doing its part to advance health care around the world.
“As a practice on the forefront of medicine, we are pleased to be able to offer clinical trials as treatment options for our patients. This will give our patients access to novel therapies that they would otherwise not have,” said Dr Emil E. Valle, of The Gastroenterology Group.
“Expanding treatment options for conditions, such as inflammatory bowel disease, is extremely important to provide optimal care. It was Elligo’s unique approach of providing clinical trial infrastructure at no cost that made offering trials feasible. We look forward to being a part of the Elligo network.”
“Elligo is delighted to be working with The Gastroenterology Group to advance the care its physicians are offering to patients,” said Dr John Potthoff, Co-Founder and CEO of Elligo Health Research.
“We provide the personnel, processes, technology and infrastructure to make the clinical research process easier for clinics at no cost, so they can focus on taking care of patients.”
